Amgen Inc.

Chdi Foundation, Inc.

Elizabeth M Doherty

Mark Henry Norman

Ning Chen

Christopher Harold Fotsch

Hui-Ling Wang

Jiawang Zhu

James Richard Falsey

Vassil I Ognyanov

Partha P Chakrabarti

Liping H Pettus

Markian Myroslaw Stec

Celia Dominguez

Xianghong Wang

Thomas Nixey

Jodie Katon

Michael G Kelly

Robert Michael Rzasa

Vijay Keshav Gore

Chenera Balan

Christopher Hulme

Premilla Arasasingham

Christopher Michael Tegley

Ning Xi

Gang Liu

Joseph L Kim

Qingyian Liu

Shimin Xu

Leslie Phillip Miranda

Qi Huang

Nianhe Han

Adrian Leonard Smith

Jerry Ryan Holder

Justin K Murray

Malgorzata Wanska

Jian Jeffrey Chen

Stephen A Hitchcock

Bin Wu

Longbin Liu

Richard Thomas Lewis

Nuria A Tamayo

Alan Findlay Haughan

Karine Fabienne Malagu

Alan C Cheng

Mark Stuart Chambers

Randall W Hungate

Michael D Croghan

Kaustav Biswas

Michele Potashman

Kelvin C Sham

Perla Breccia

Andrew J Stott

Nick A Paras

Huw David Vater

Yunxin Y Bo

Marian C Bryan

Matthew Randolf Lee

Ingrid M Fellows

Frenel Fils De Morin

Douglas A Whittington

Daniel Martin Retz

Jason C Long

Jeffrey Petkus

Duncan M Smith

William R K Esmieu

Amanda J Van De Poël

Stephen John Webster

Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.

HTT modulators for treating Huntington's disease

Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Na1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Na1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.

Potent and selective inhibitors of Nav1.7

[object Object]

The present invention describes pyrimidine compounds of Formula I that are useful as anaplastic lymphoma kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.

Pyrimidine compounds that inhibit anaplastic lymphoma kinase

The present invention comprises a new class of compounds capable of modulating the activity of Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula (I) wherein each of A, A, A, A, A, A, A, A, A, bond B, X, rings Zand Z, Rand Rare defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention. 

RAF kinase modulators and methods of use

The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula I wherein Ris and A, A, A, A, X, Z, Z', R, R, R, R, Rand Rare defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

Substituted pyrimidine compounds as RAF inhibitors and methods of use

Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

Vanilloid receptor ligands and their use in treatments

Pyrimidine ethers and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

Growing community of inventors

Newbury Park, CA, United States of America

Elizabeth M Doherty